Predictive Oncology (POAI) 10-Q 15 Nov 19 2019 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 14, 2019
Document Information [Line Items]
Entity Registrant Name	Predictive Oncology Inc.
Entity Central Index Key	0001446159
Trading Symbol	poai
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		3,887,956
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common Stock, $0.01 par value

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and Cash Equivalents	$ 98,599	$ 162,152
Accounts Receivable	372,119	232,602
Notes Receivable (inclusive of $0 and $452,775 in advances to Helomics; net of $787,524 and $0 in allowance for credit losses)	250,000	497,276
Inventories	210,350	241,066
Prepaid Expense and other assets	131,558	318,431
Total Current Assets	1,062,626	1,451,527
Notes Receivable		1,112,524
Fixed Assets, net	1,633,750	180,453
Intangibles, net	4,508,433	964,495
Lease Right-of-Use Assets	886,712
Goodwill	23,790,290
Total Assets	31,881,811	3,708,999
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	3,762,468	445,689
Notes Payable –Net of Discounts of $499,215 and $1,032,814	4,470,380	1,634,914
Accrued Expenses	1,807,188	1,279,114
Derivative Liability	210,762	272,745
Deferred Revenue	30,638	23,065
Lease Liability – Net of Long-term Portion	500,732
Total Current Liabilities	10,782,168	3,655,527
Lease Liability	385,980
Total Liabilities	11,168,148	3,655,527
Stockholders’ Equity:
Common Stock, $.01 par value, 100,000,000 shares authorized, 3,149,751 and 1,409,175 outstanding	31,497	14,092
Additional paid-in capital	89,590,908	63,146,533
Accumulated Deficit	(68,944,537)	(63,107,945)
Total Stockholders' Equity	20,713,663	53,472
Total Liabilities and Stockholders' Equity	31,881,811	3,708,999
Series E Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock	3
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock	792	792
Series D Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock	$ 35,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Notes receivable	$ 250,000	$ 497,276
Reserve for bad debt	787,524	0
Discount of note payable	$ 499,215	$ 1,032,814
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares outstanding (in shares)	3,149,751	1,409,175
Series E Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	350	350
Preferred stock, shares outstanding (in shares)	257.7	0
Preferred stock, liquidation value	$ 2,577,000	$ 2,577,000
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	79,246	79,246
Series D Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	3,500,000	0
Helomics Holding [Member]
Notes receivable	$ 0	$ 452,775

Condensed Consolidated Statemen

Condensed Consolidated Statements of Net Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue	$ 522,696	$ 329,930	$ 1,064,088	$ 1,100,108
Cost of goods sold	208,096	83,006	400,202	309,320
Gross margin	314,600	246,924	663,886	790,788
General and administrative expense	2,616,991	762,603	7,425,305	2,708,274
Operations expense	707,414	723,939	2,445,238	1,390,434
Sales and marketing expense	434,955	621,465	1,674,200	1,726,087
Total operating loss	(3,444,760)	(1,861,083)	(10,880,857)	(5,034,007)
Gain on revaluation of cash advances to Helomics			1,222,244
Other income	15,084		65,293
Other expense	578,836		1,967,895
Loss on equity method investment		645,786	439,637	1,606,294
Gain on revaluation of equity method investment			6,164,260
Net loss	(4,008,512)	(2,506,869)	(5,836,592)	(6,640,301)
Deemed dividend on Series E Convertible Preferred Stock	125,801		146,199
Net loss attributable to common shareholders per common shares – basic and diluted	$ (4,134,313)	$ (2,506,869)	$ (5,982,791)	$ (6,640,301)
Loss per common share - basic and diluted (in dollars per share)	$ (1.31)	$ (1.89)	$ (2.32)	$ (5.45)
Weighted average shares used in computation - basic and diluted (in shares)	3,146,609	1,325,261	2,581,014	1,217,829

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Series E Warrants [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Re-priced Warrants [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Warrants Issued to CEO [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Expense Warrant for Note Extension [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Warrant for Promissory Notes [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Warrants Issued to Helomics' Investors [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Warrants Held by Noteholders [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Private Placement [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Over-Allotment Option [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Chief Executive Officer [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Bridge Notes [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Helomics Acquisition, Inc. [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Consulting Agreement One [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Contract with TumorGenesis [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]TumorGenesis [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]Warrants Issued to CEO [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]Expense Warrant for Note Extension [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]Warrant for Promissory Notes [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]Warrants Issued to Helomics' Investors [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]Warrants Held by Noteholders [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]Private Placement [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]Chief Executive Officer [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]Bridge Notes [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Warrants Issued to CEO [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Expense Warrant for Note Extension [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Warrant for Promissory Notes [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Warrants Issued to Helomics' Investors [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Warrants Held by Noteholders [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Private Placement [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Chief Executive Officer [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Bridge Notes [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]Series E Warrants [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]Re-priced Warrants [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]Private Placement [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]Over-Allotment Option [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]Bridge Notes [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]Helomics Acquisition, Inc. [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]TumorGenesis [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]	Common Stock [Member]Series E Warrants [Member]	Common Stock [Member]Re-priced Warrants [Member]	Common Stock [Member]Warrants Issued to CEO [Member]	Common Stock [Member]Expense Warrant for Note Extension [Member]	Common Stock [Member]Warrant for Promissory Notes [Member]	Common Stock [Member]Warrants Issued to Helomics' Investors [Member]	Common Stock [Member]Warrants Held by Noteholders [Member]	Common Stock [Member]Private Placement [Member]	Common Stock [Member]Over-Allotment Option [Member]	Common Stock [Member]Chief Executive Officer [Member]	Common Stock [Member]Bridge Notes [Member]	Common Stock [Member]Helomics Acquisition, Inc. [Member]	Common Stock [Member]Consulting Agreement One [Member]	Common Stock [Member]Contract with TumorGenesis [Member]	Common Stock [Member]TumorGenesis [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]Series E Warrants [Member]	Additional Paid-in Capital [Member]Re-priced Warrants [Member]	Additional Paid-in Capital [Member]Warrants Issued to CEO [Member]	Additional Paid-in Capital [Member]Expense Warrant for Note Extension [Member]	Additional Paid-in Capital [Member]Warrant for Promissory Notes [Member]	Additional Paid-in Capital [Member]Warrants Issued to Helomics' Investors [Member]	Additional Paid-in Capital [Member]Warrants Held by Noteholders [Member]	Additional Paid-in Capital [Member]Private Placement [Member]	Additional Paid-in Capital [Member]Over-Allotment Option [Member]	Additional Paid-in Capital [Member]Chief Executive Officer [Member]	Additional Paid-in Capital [Member]Bridge Notes [Member]	Additional Paid-in Capital [Member]Helomics Acquisition, Inc. [Member]	Additional Paid-in Capital [Member]Consulting Agreement One [Member]	Additional Paid-in Capital [Member]Contract with TumorGenesis [Member]	Additional Paid-in Capital [Member]TumorGenesis [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]Series E Warrants [Member]	Retained Earnings [Member]Re-priced Warrants [Member]	Retained Earnings [Member]Warrants Issued to CEO [Member]	Retained Earnings [Member]Expense Warrant for Note Extension [Member]	Retained Earnings [Member]Warrant for Promissory Notes [Member]	Retained Earnings [Member]Warrants Issued to Helomics' Investors [Member]	Retained Earnings [Member]Warrants Held by Noteholders [Member]	Retained Earnings [Member]Private Placement [Member]	Retained Earnings [Member]Over-Allotment Option [Member]	Retained Earnings [Member]Chief Executive Officer [Member]	Retained Earnings [Member]Bridge Notes [Member]	Retained Earnings [Member]Helomics Acquisition, Inc. [Member]	Retained Earnings [Member]Consulting Agreement One [Member]	Retained Earnings [Member]Contract with TumorGenesis [Member]	Retained Earnings [Member]TumorGenesis [Member]	Retained Earnings [Member]	Series E Convertible Preferred Stock [Member]	Series E Warrants [Member]	Re-priced Warrants [Member]	Warrants Issued to CEO [Member]	Expense Warrant for Note Extension [Member]	Warrant for Promissory Notes [Member]	Warrants Issued to Helomics' Investors [Member]	Warrants Held by Noteholders [Member]	Private Placement [Member]	Over-Allotment Option [Member]	Chief Executive Officer [Member]	Bridge Notes [Member]	Helomics Acquisition, Inc. [Member]	Consulting Agreement One [Member]	Contract with TumorGenesis [Member]	TumorGenesis [Member]	Total
Balance (in shares) at Dec. 31, 2017																79,246																										647,819																694,328
Balance at Dec. 31, 2017																$ 792																										$ 6,479																$ 6,943																$ 57,442,745																$ (54,765,045)																	$ 2,691,914
Warrant exercises (in shares)																																											14,539	50,467
Warrant exercises																																											$ 145	$ 505															$ 145,251	$ 504,160																																$ 145,396	$ 504,665
Shares issued for services (in shares)																																																										25,000
Shares issued for services																																																										$ 250																294,750																																	295,000
Shares issued in escrow pursuant to a contract with TumorGenesis at $11.70 per share (in shares)																																																									75,000
Shares issued in escrow pursuant to a contract with TumorGenesis at $11.70 per share																																																									$ 750																$ 876,750																																	$ 877,500
Stock issuable for bridge loan																																																																					$ 206,605																																	$ 206,605
Warrants issued per bridge loan																																																																										143,707																																	143,707
Vesting Expense																																																																										800,322																																	800,322
Net loss																																																																																										(6,640,301)																	(6,640,301)
Preferred conversion to common shares pursuant to private placement agreement (in shares)																																					(647,819)													58,975
Preferred conversion to common shares pursuant to private placement agreement																																					$ (6,479)													$ 590																$ 5,889																																									(6,479)
Shares issued (in shares)																																																			21,525							290,000
Shares issued																																																			$ 215							$ 2,900									$ 204,206							2,752,187																										$ 204,422							2,755,087
Shares issued for acquisition (in shares)																																																						110,000
Shares issued for acquisition																																																						$ 1,100																$ 1,041,150																																	$ 1,042,250
Shares issued																																																																																			$ 1
Balance (in shares) at Sep. 30, 2018																79,246																																										1,339,834
Balance at Sep. 30, 2018																$ 792																																										$ 13,398																64,417,722																(61,405,345)																	3,026,567
Balance (in shares) at Jun. 30, 2018																79,246																																										1,208,945
Balance at Jun. 30, 2018																$ 792																																										$ 12,089																62,247,373																(58,898,476)																	3,361,778
Warrant exercises (in shares)																																											5,656	25,233
Warrant exercises																																											$ 57	$ 252															$ 56,503	$ 252,080																																$ 56,560	$ 252,332
Shares issued for services (in shares)																																																							25,000
Shares issued for services																																																							$ 250																$ 294,750																																	$ 295,000
Shares issued in escrow pursuant to a contract with TumorGenesis at $11.70 per share (in shares)																																																								75,000
Shares issued in escrow pursuant to a contract with TumorGenesis at $11.70 per share																																																								$ 750																$ 876,750																																	$ 877,500
Stock issuable for bridge loan																																																																										206,605																																	206,605
Warrants issued per bridge loan																																																																										143,707																																	143,707
Vesting Expense																																																																										339,954																																	339,954
Net loss																																																																																										(2,506,869)																	(2,506,869)
Balance (in shares) at Sep. 30, 2018																79,246																																										1,339,834
Balance at Sep. 30, 2018																$ 792																																										$ 13,398																64,417,722																(61,405,345)																	3,026,567
Balance (in shares) at Dec. 31, 2018																79,246																																										1,409,175
Balance at Dec. 31, 2018																$ 792																																										$ 14,092																63,146,533																(63,107,945)																	53,472
Warrant exercises (in shares)																																																										59,700
Warrant exercises																																																										$ 597																5,373																																	5,970
Warrants issued per bridge loan																																																													$ 356,471		$ 180,640	$ 6,261,590	$ 177,343																													$ 356,471		$ 180,640	$ 6,261,590	$ 177,343
Vesting Expense																																																																										2,004,366																																	2,004,366
Net loss																																																																																										(5,836,592)																	(5,836,592)
Shares issued pursuant to debt (in shares)																																																					23,857					82,432
Shares issued pursuant to debt																																																					$ 239					$ 824											119,135					337,749																												119,374					338,573
Issuance of Series E Preferred shares (in shares)																																		257.7																																																									257.7
Issuance of Series E Preferred shares																																		$ 3																																								2,338,837																																	2,338,840
Preferred conversion to common shares pursuant to private placement agreement
Shares issued (in shares)																																																		286,375		7,813
Shares issued																																																		$ 2,864		$ 78														$ 2,426,844		$ 49,922																							$ 2,577,000								$ 2,429,708		$ 50,000
Shares issued for acquisition (in shares)																									3,500,000																																	400,000
Shares issued for acquisition																									$ 35,000																																	$ 4,000																5,573,250																																	5,612,250
Shares issued in forbearance agreement (in shares)																																																										16,667
Shares issued in forbearance agreement																																																										$ 166																158,183																																	158,349
Stock issued to extinguish debt as part of Helomics purchase consideration (in shares)																																																										863,732
Value of shares to extinguish debt (iii)																																																										$ 8,637																6,454,672																																	6,463,309
Balance (in shares) at Sep. 30, 2019																79,246									3,500,000									257.7																								3,149,751
Balance at Sep. 30, 2019																$ 792									$ 35,000									$ 3																								$ 31,497																89,590,908																(68,944,537)																	20,713,663
Balance (in shares) at Jun. 30, 2019																79,246									3,500,000									84.3																								3,097,476
Balance at Jun. 30, 2019																$ 792									$ 35,000									$ 1																								$ 30,975																87,160,845																(64,936,025)																	22,291,588
Warrant exercises (in shares)																																																										1,844
Warrant exercises																																																										$ 18																166																																	184
Warrants issued per bridge loan																																																													$ 14,863	$ 60,100	$ 180,640																															$ 14,863	$ 60,100	$ 180,640
Vesting Expense																																																																										360,146																																	360,146
Net loss																																																																																										(4,008,512)																	(4,008,512)
Shares issued pursuant to debt (in shares)																																																					23,858					26,573
Shares issued pursuant to debt																																																					$ 238					$ 266											$ 119,136					99,734																												$ 119,374					100,000
Issuance of Series E Preferred shares (in shares)																																		173.4																																																									173.4
Issuance of Series E Preferred shares																																		$ 2																																								1,595,278																																	1,595,280
Balance (in shares) at Sep. 30, 2019																79,246									3,500,000									257.7																								3,149,751
Balance at Sep. 30, 2019																$ 792									$ 35,000									$ 3																								$ 31,497																$ 89,590,908																$ (68,944,537)																	$ 20,713,663

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals)	Sep. 30, 2018$ / shares
Series E Warrants [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 10
Consulting Agreement One [Member]
Price of shares issued (in dollars per share)	11.80
Contract with TumorGenesis [Member]
Price of shares issued (in dollars per share)	11.70
TumorGenesis [Member]
Price of shares issued (in dollars per share)	11.70
Over-Allotment Option [Member]
Price of shares issued (in dollars per share)	9.497
Price of shares issued (in dollars per share)	$ 11.80

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flow from operating activities:
Net loss	$ (5,836,592)	$ (6,640,301)
Adjustments to reconcile net loss to net cash used in operating activities:
Recognition of credit loss on notes receivable	787,524
Accrued interest revenue	(34,917)
Loss on equity method investment	439,637	1,606,294
Gain on revaluation of equity method investment	(6,164,260)
Depreciation and amortization	483,631	105,569
Vesting expense	2,004,366	800,322
Equity instruments issued for management and consulting		295,000
Amortization of debt discount	1,621,181
Gain on valuation of equity-linked instruments	(84,627)
Gain on revaluation of cash advances to Helomics	(1,222,244)
Debt extinguishment costs	204,750
Loss on fixed asset disposal	293
Changes in assets and liabilities:
Accounts receivable	68,252	(101,099)
Inventories	60,638	(13,110)
Prepaid expense and other assets	33,834	70,536
Accounts payable	942,183	268,637
Accrued expenses	751,975	(470,176)
Deferred revenue	7,573	8,643
Net cash used in operating activities	(5,936,803)	(4,069,685)
Cash flow from investing activities:
Redemption of certificates of deposit		244,971
Advance on notes receivable	(975,000)	(124,774)
Cash received from notes receivable	154,418
Cash received in Helomics Acquisition	248,102
Purchase of fixed assets	(855)	(169,983)
Acquisition of intangibles	(18,419)	(46,398)
Net cash used in investing activities:	(591,754)	(96,184)
Cash flow from financing activities:
Proceeds from debt issuance	2,250,000
Repayment of debt	(609,514)
Proceeds from exercise of warrants into common stock	5,970	650,062
Proceeds from issuance of Series E convertible preferred stock	2,338,840
Issuance of common stock	2,479,708	2,959,509
Net cash provided by financing activities	6,465,004	3,609,571
Net decrease in cash and cash equivalents	(63,553)	(556,298)
Cash at beginning of period	162,152	766,189
Cash at end of period	98,599	209,891
Non-cash transactions:
Bridge loan conversion into common stock	338,573
Forbearance settlement bridge loan	503,009
Value of warrants issued (iv)	47,078
Warrants issued pursuant to debt issuance	180,640
Consideration given for acquisition of Helomics	26,711,791	1,542,250
Shares issued into escrow for TumorGenesis		877,500
Bridge loan receivable		1,815,000
Conversion of preferred stock to common stock		$ 6,479

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 Nature of Operations and Continuance of Operations Predictive Oncology Inc., (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. June 10, 2019, June 13, 2019. October 28, 2019, one ten October 29, 2019. The Company is a healthcare company that provides personalized medicine solution and medical devices in two 1 2 On April 4, 2019, 149,000 first 2018, The Company has incurred recurring losses from operations and has an accumulated deficit of $68,944,537. not no may $98,599 September 30, 2019 may third 2019, $1,562,840 $25,000 $2,811,309 October 2019 ( 9 October 2019, $15,000,000 three one not Interim Financial Statements The Company has prepared the financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations, and its cash flows for the interim periods. These interim financial statements reflect all intercompany eliminations. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Annual Report on Form 10 April 1, 2019. may not Recent Accounting Developments The Company has reviewed all recently issued accounting pronouncements and has determined that they are either not not In February 2016, No. 2016 02, Leases (Topic 842 2016 02” December 15, 2018. January 1, 2019, $353,007 $79,252 2016 02 not Accounting Policies and Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities at the date of the financial statements during the reporting period. Actual results could materially differ from those estimates. The Company leases facilities under long-term operating leases that are non-cancelable and expire on various dates. At the lease commencement date, lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term, which includes all fixed obligations arising from the lease contract. If an interest rate is not See Note 8 Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three Fair Value Measurements Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC) 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities was determined based on Level 1 Inventories Inventories are stated at the net realizable value, with cost determined on a first first September 30, December 31, Finished goods $ 62,696 $ 58,701 Raw materials 86,413 127,003 Work-In-Process 61,241 55,362 Total $ 210,350 $ 241,066 Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Depreciation of fixed assets is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 2 Manufacturing tooling 3 - 7 Demo equipment 3 Laboratory equipment 4 The Company’s fixed assets consist of the following: September 30, December 31, Computers and office equipment $ 504,556 $ 204,903 Leasehold improvements 188,014 140,114 Manufacturing tooling 108,955 108,955 Demo equipment 73,051 85,246 Laboratory equipment 1,401,210 - Total 2,275,786 539,218 Less: Accumulated depreciation 642,036 358,765 Total Fixed Assets, Net $ 1,633,750 $ 180,453 The large fluctuation in fixed assets is due to the Helomics acquisition. Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred. Depreciation expense was $130,848 $284,150 three nine September 30, 2019 $26,120 $59,442 three nine September 30, 2018. Intangible Assets Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, and customer relationships, and are amortized over their estimated useful life. The tradename is an indefinite-lived intangible asset and is not $93,421 $199,481 three nine September 30, 2019 $38,387 $46,127 three nine September 30, 2018. 360 Property, Plant and Equipment may not may not not The large fluctuation in intangible assets during 2019 The components of intangible assets were as follows: 9/30/2019 12/31/2018 Gross Carrying Accumulated Net Carrying Gross Carrying Accumulated Net Carrying Patents & Trademarks $ 336,722 $ (191,950 ) $ 144,772 $ 318,304 $ (182,559 ) $ 135,745 Licensing Fees 877,500 (92,625 ) 784,875 877,500 (48,750 ) 828,750 Developed Technology 2,882,000 (72,048 ) 2,809,952 - - - Customer Relationships 445,000 (74,166 ) 370,834 - - - Tradename 398,000 - 398,000 - - - Total $ 4,939,222 $ (430,789 ) $ 4,508,433 $ 1,195,804 $ (231,309 ) $ 964,495 The following table outlines the estimated future amortization expense related to intangible assets held as of September 30, 2019: Year ending December 31, Expense 2019 90,985 2020 363,941 2021 363,941 2022 265,053 2023 215,609 Thereafter 2,810,904 Total 4,110,433 Goodwill In accordance with ASC - 350, Intangibles – Goodwill and Other, not not first not may first not 2018; no September 30, 2019, not not 2019 fourth 2019. Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Under Internal Revenue Code Section 382 may not not 382 may 382 2020. Tax years subsequent to 2015 Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred. Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one no Segments The Company has five three nine September 30, 2019 2018, Three Months Ended September 30, Nine Months Ended September 30, 2019 2019 Domestic International Corporate/Other Total Domestic International Corporate/Other Total Revenue $ 455,878 $ 40,006 $ 26,812 $ 522,696 $ 934,621 $ 77,051 $ 52,416 $ 1,064,088 Segment Loss $ (838,742 ) $ (92,398 ) $ (3,077,372 ) $ (4,008,512 ) $ (2,697,338 ) $ (289,492 ) $ (2,849,762 ) $ (5,836,592 ) September 30, 2019 December 31, 2018 Domestic International Corporate/Other Total Domestic International Corporate/Other Total Net Assets $ (284,805 ) $ (10,387 ) $ 21,008,855 $ 20,713,663 $ 628,451 $ 41,377 $ (616,356 ) $ 53,472 Risks and Uncertainties The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not

Note 2 - Helomics Acquisition

Note 2 - Helomics Acquisition	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Business Combination Disclosure [Text Block]	NOTE 2 The Company acquired 25% first 2018. April 4, 2019, ( 75% Helomics’ precision medicine services are designed to use artificial intelligence and a comprehensive disease database to improve the effectiveness of cancer therapy. Helomics’ precision oncology services are based on its D-CHIP diagnostic platform, which combines a database of genomic and drug response profiles from over 149,000 The acquisition of Helomics was accounted for as a business combination using the acquisition method of accounting. This method requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date. The fair value for the assets acquired and the liabilities assumed are based on information knowable and determined by management as of the date of this filing. The Company incurred $656,615 The fair value of the consideration transferred in the acquisition has five $26,711,791. Value of shares to Helomics shareholders (i) $ 5,612,250 Value of Helomics notes receivable forgiven (ii) 2,210,381 Value of shares to extinguish debt (iii) 6,463,309 Value of warrants issued (iv) 6,261,591 Gain on revaluation of equity method investment (v) 6,164,260 Fair value of the consideration $ 26,711,791 Less assets acquired: Cash & cash equivalents 248,102 Accounts receivable 207,769 Inventory 17,727 Prepaid expenses 15,321 Fixed assets, net 1,749,080 Intangible assets 3,725,000 Lease right of use assets 780,594 Plus liabilities assumed: Accounts payable 2,374,596 Note Payable 303,333 Accrued expenses 363,569 Lease Liability – Net of Long-term Portion 422,126 Lease liability 358,468 Total assets acquired and liabilities assumed (2,921,501 ) Goodwill $ 23,790,290 (i) Upon the acquisition, all outstanding shares of Helomics stock not 4,000,000 3,500,000 $5,612,250; $2,210,381; 8,637,323 $6,463,309; 14,245,063 23,741,772 597,000 $6,261,591; 25% 2018 $6,164,260 75% 10% The fair values of all common and preferred shares issued as consideration in the transaction was determined using the closing bid price of the Company’s common stock on April 4, 2019. The Company did not three not $303,333 90 583,003 $1.00 Identifiable Intangible Assets The Company acquired intangible assets related to trademarks for the acquired Helomics trade name with an estimated fair market value of $398,000. The Company acquired intangible assets with a useful life of three $445,000 The Company acquired intangible assets with a useful life of 20 $2,882,000 The acquisition costs related to the intangible assets are presented in legal and accounting expenses within general and administrative expenses in the statement of net loss. Goodwill The $23,790,290 None three Financial Results The financial results of Helomics since the acquisition date have been included in the Company’s unaudited condensed consolidated statements of net loss for the quarter. Pro Forma The following pro forma information presents the combined results of operations of Predictive Oncology and Helomics as if the acquisition of Helomics had been completed on January 1, 2019, April 4, 2019, no three September 30, 2019. Nine Months Ended September 30, 2019 Revenue $ 1,110,148 Net loss attributable to Predictive $ 7,249,123 The primary adjustments include the deduction of the original depreciation and amortization and the inclusion of the revalued depreciation and amortization for Helomics tangible and intangible assets. The unaudited pro forma results do not may not There are certain portions of purchase accounting, specifically Section 382 Tax Loss Carryforwards not may

Note 3 - Revenue Recognition

Note 3 - Revenue Recognition	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	NOTE 3 The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected an accounting policy to exclude sales taxes from revenue and expenses. Revenue from Product Sales The Company has medical device revenue consisting primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. This revenue stream is reported within both the domestic and international revenue segments. The Company sells its medical device products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and acceptance of its Terms and Conditions to be a customer’s contract in all cases. Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) the Company has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from the Company’s facilities (“FOB origin,” which is the Company’s standard shipping terms). As a result, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. Revenue from Clinical Testing The Precision Oncology Insights are clinic diagnostic testing comprised of the Company’s ChemoFx and BioSpeciFx tests. The ChemoFx test determines how a patient’s tumor specimen reacts to a panel of various chemotherapy drugs, while the BioSpeciFx test evaluates the expression of a particular gene related to a patient’s tumor specimen. Revenues are recognized when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The estimated uncollectible amounts are generally considered implicit price concessions that are a reduction in revenue. Helomics payments terms vary by the agreements reached with insurance carriers and Medicare. The Company’s performance obligations are satisfied at one 1 For service revenues, the Company estimates the transaction price which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a patient, it will account for the change as an increase to the estimate of the transaction price, provided that such downward adjustment does not The Company recognizes revenue from these patients when contracts as defined in ASC 606, Revenue from Contracts with Customers CRO Revenue Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company typically uses an input method that recognizes revenue based on the Company’s efforts to satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation on the basis of the standalone selling price of each distinct good or service in the contract. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met. Payment terms are net 30 1 Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not Warranty The Company generally provides one no not Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of September 30, 2019, December 31, 2018, $372,119 $232,602, The Company’s deferred revenues related primarily to maintenance plans and CRO revenue of $30,638 $23,065 September 30, 2019 December 31, 2018, Practical Expedients The Company has elected the practical expedient not

Note 4 - Stockholders' Equity,

Note 4 - Stockholders' Equity, Stock Options and Warrants	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 4 Series D Preferred Shares In April 2019, 3,500,000 10:1 50% one April 4, 2020. Series E Convertible Preferred Stock In June September 2019, $1,734,000 2,577,000 three nine September 30, 2019, three nine September 30, 2019, 173.4 257.7 $182,000 $289,936 three nine September 30, 2019, six September 30, 2019, Each Preferred Share Holder shall have the right at the Company’s option to be converted into 0.056857% six June 13, 2019. 12 Net Loss Attributable to common shareholders The net loss attributable to common shareholders for the three nine September 30, 2019, $2,577,000 $182,000 $289,936 three nine September 30, 2019, The Series E convertible preferred stock is not not September 30, 2019, December 13, 2019 $125,801 $146,199 three nine September 30, 2019, not 7 Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three three ten Valuation and accounting for options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. For grants of stock options and warrants issued during the quarter ended September 30, 2019, 1.39% 2.03% 0% 82.4% 5 10 $3.368 $6.527 The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2017 276,498 $ 19.95 195,126 $ 237.40 Issued 109,886 10.13 233,615 10.67 Expired (19,456 ) 20.00 (1,071 ) 1,995.53 Exercised - - (65,006 ) 10.00 Outstanding at December 31, 2018 366,928 $ 17.03 362,664 $ 41.67 Issued 366,120 7.12 1,805,943 9.36 Expired (19,484 ) 14.73 (630 ) 3,258.32 Exercised - - (59,700 ) 0.10 Outstanding at September 30, 2019 713,564 $ 11.84 2,108,277 $ 15.33 Stock-based compensation expense recognized for the three nine September 30, 2019 $360,146 $2,004,366, three nine September 30, 2018 $339,954 $800,322, $310,403 16

Note 5 - Notes Receivable

Note 5 - Notes Receivable	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Financing Receivables [Text Block]	NOTE 5 The Company has a secured promissory note receivable from CytoBioscience for $1,112,524, 8% February 28, 2020. 2019, first April 2019. not first $1,290,000. $250,000

Note 6 - Convertible Debt and D

Note 6 - Convertible Debt and Derivative Liability	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Convertible Debt and Derivative Liability [Text Block]	NOTE 6 Bridge Loan Effective September 28, 2018, two $2,297,727 September 28, 2019. September 27, 2019, one September 27, 2019, December 31, 2019 $120,000 15,000 third $100,000 26,573 September 30, 2019 $1,878,295. The bridge loan accrues interest at a rate of 8% 20 may 267,833 Promissory Note Effective September 27, 2019, $847,500 $700,000. March 27, 2020. 8,858 68,237 $6.210 sixth fifth 8% Derivative Liability Management has concluded the bridge loan contains a conversion feature which is an embedded derivative that is required to be bifurcated and separately presented as a liability on the balance sheet. The embedded derivative’s value was determined using discounted stock price for the 20 $84,627 nine September 30, 2019. September 30, 2019 $188,118. The value of the embedded derivative from the bridge loan as well as the derivative included in the note payable agreements with the Company’s CEO (see Note 9 3 1. nine September 30, 2019. Derivative Liability Derivative Gain Recognized to Adjustments to Derivative Liability $ 272,745 69,722 (84,627 ) (47,078 ) $ 210,762

Note 7 - Loss Per Share

Note 7 - Loss Per Share	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 7 The following table presents the shares used in the basic and diluted loss per common share computations: Three Months Ended September 30 Nine Months Ended September 30 2019 2018 2019 2018 Numerator: Net loss attributable to common shareholders per common share: basic and diluted calculation $ (4,134,313 ) $ (2,506,869 ) $ (5,982,791 ) $ (6,640,301 ) Denominator: Weighted average common shares outstanding-basic 3,146,609 1,325,261 2,581,014 1,217,829 Effect of diluted stock options, warrants and preferred stock (1) - - - - Weighted average common shares outstanding-diluted 3,146,609 1,325,261 2,581,014 1,217,829 Loss per common share-basic and diluted $ (1.31 ) $ (1.89 ) $ (2.32 ) $ (5.45 ) ( 1 Three and Nine Months Ended 2019 2018 Options 713,564 344,889 Warrants 2,108,277 331,927 Convertible debt 103,734 504,770 Preferred stock: series B 7,925 7,925 Preferred stock: series D 350,000 - Preferred stock: series E 461,503 -

Note 8 - Leases

Note 8 - Leases	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	NOTE 8 The Company’s corporate offices are located in Eagan, Minnesota. The lease as amended has a three January 31, 2021. 5,773 2,945 2,828 Skyline Medical Europe’s offices are located in Belgium. The Company leases around 2,000 750 1,250 June 14, 2027. Helomics’ offices are located in Pittsburgh, Pennsylvania. The lease, as amended, has a three January 31, 2021. 17,417 1,000 16,417 Lease expense was $184,046 $367,180 three nine September 30, 2019 $27,807 $64,986 three nine September 30, 2018, The following table summarizes other information related to the Company’s operating leases: September 30, 2019 Weighted average remaining lease term – operating leases in years 3.06 Weighted average discount rate – operating leases 8 % The Company’s rent obligation is as follows: 2019 $ 129,546 2020 519,751 2021 117,722 2022 42,124 2023 42,966 2024 and thereafter 153,278 Total lease payments 1,005,387 Less interest 118,675 Present value of lease liabilities $ 886,712

Note 9 - Related Party Transact

Note 9 - Related Party Transactions	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 9 The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may One of the Company’s directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Another Company director, Tim Krochuk, is on the supervisory board for GLG. The Company and GLG have a partnership agreement with Helomics for the purpose of bringing together their proprietary technologies to build out personalized medicine platform for the diagnosis and treatment of women’s cancer. There has been no On May 1, 2019, one three $13,500 On May 21, 2019, third second $1,620,000. 3,451 third $14,863. September 30, 2019, $22,644. During 2019, $300,000 8% December 31, 2019. No not

Note 10 - Subsequent Events

Note 10 - Subsequent Events	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 10 Public Offering On October 1, 2019, 633,554 October 4, 2019. $5.00 $3,167,769, $2,811,309. In addition, the Company granted warrants to the placement agents to purchase up to 63,355 10% $6.25. Reverse Stock Split On October 28, 2019, one ten October 29, 2019. Equity Line Arrangement On October 24, 2019, $15,000,000 three 104,651 three may

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Nature of Operations and Continuance of Operations Predictive Oncology Inc., (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. June 10, 2019, June 13, 2019. October 28, 2019, one ten October 29, 2019. The Company is a healthcare company that provides personalized medicine solution and medical devices in two 1 2 On April 4, 2019, 149,000 first 2018, The Company has incurred recurring losses from operations and has an accumulated deficit of $68,944,537. not no may $98,599 September 30, 2019 may third 2019, $1,562,840 $25,000 $2,811,309 October 2019 ( 9 October 2019, $15,000,000 three one not
Interim Financial Statements, Policy [Policy Text Block]	Interim Financial Statements The Company has prepared the financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations, and its cash flows for the interim periods. These interim financial statements reflect all intercompany eliminations. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Annual Report on Form 10 April 1, 2019. may not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Developments The Company has reviewed all recently issued accounting pronouncements and has determined that they are either not not In February 2016, No. 2016 02, Leases (Topic 842 2016 02” December 15, 2018. January 1, 2019, $353,007 $79,252 2016 02 not Accounting Policies and Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities at the date of the financial statements during the reporting period. Actual results could materially differ from those estimates. The Company leases facilities under long-term operating leases that are non-cancelable and expire on various dates. At the lease commencement date, lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term, which includes all fixed obligations arising from the lease contract. If an interest rate is not See Note 8
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC) 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities was determined based on Level 1
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the net realizable value, with cost determined on a first first September 30, December 31, Finished goods $ 62,696 $ 58,701 Raw materials 86,413 127,003 Work-In-Process 61,241 55,362 Total $ 210,350 $ 241,066
Property, Plant and Equipment, Policy [Policy Text Block]	Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Depreciation of fixed assets is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 2 Manufacturing tooling 3 - 7 Demo equipment 3 Laboratory equipment 4 The Company’s fixed assets consist of the following: September 30, December 31, Computers and office equipment $ 504,556 $ 204,903 Leasehold improvements 188,014 140,114 Manufacturing tooling 108,955 108,955 Demo equipment 73,051 85,246 Laboratory equipment 1,401,210 - Total 2,275,786 539,218 Less: Accumulated depreciation 642,036 358,765 Total Fixed Assets, Net $ 1,633,750 $ 180,453 The large fluctuation in fixed assets is due to the Helomics acquisition. Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred. Depreciation expense was $130,848 $284,150 three nine September 30, 2019 $26,120 $59,442 three nine September 30, 2018.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, and customer relationships, and are amortized over their estimated useful life. The tradename is an indefinite-lived intangible asset and is not $93,421 $199,481 three nine September 30, 2019 $38,387 $46,127 three nine September 30, 2018. 360 Property, Plant and Equipment may not may not not The large fluctuation in intangible assets during 2019 The components of intangible assets were as follows: 9/30/2019 12/31/2018 Gross Carrying Accumulated Net Carrying Gross Carrying Accumulated Net Carrying Patents & Trademarks $ 336,722 $ (191,950 ) $ 144,772 $ 318,304 $ (182,559 ) $ 135,745 Licensing Fees 877,500 (92,625 ) 784,875 877,500 (48,750 ) 828,750 Developed Technology 2,882,000 (72,048 ) 2,809,952 - - - Customer Relationships 445,000 (74,166 ) 370,834 - - - Tradename 398,000 - 398,000 - - - Total $ 4,939,222 $ (430,789 ) $ 4,508,433 $ 1,195,804 $ (231,309 ) $ 964,495 The following table outlines the estimated future amortization expense related to intangible assets held as of September 30, 2019: Year ending December 31, Expense 2019 90,985 2020 363,941 2021 363,941 2022 265,053 2023 215,609 Thereafter 2,810,904 Total 4,110,433
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill In accordance with ASC - 350, Intangibles – Goodwill and Other, not not first not may first not 2018; no September 30, 2019, not not 2019 fourth 2019.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Under Internal Revenue Code Section 382 may not not 382 may 382 2020. Tax years subsequent to 2015
Offering Costs [Policy Text Block]	Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one no
Segment Reporting, Policy [Policy Text Block]	Segments The Company has five three nine September 30, 2019 2018, Three Months Ended September 30, Nine Months Ended September 30, 2019 2019 Domestic International Corporate/Other Total Domestic International Corporate/Other Total Revenue $ 455,878 $ 40,006 $ 26,812 $ 522,696 $ 934,621 $ 77,051 $ 52,416 $ 1,064,088 Segment Loss $ (838,742 ) $ (92,398 ) $ (3,077,372 ) $ (4,008,512 ) $ (2,697,338 ) $ (289,492 ) $ (2,849,762 ) $ (5,836,592 ) September 30, 2019 December 31, 2018 Domestic International Corporate/Other Total Domestic International Corporate/Other Total Net Assets $ (284,805 ) $ (10,387 ) $ 21,008,855 $ 20,713,663 $ 628,451 $ 41,377 $ (616,356 ) $ 53,472
Risks and Uncertainties Policy [Policy Text Block]	Risks and Uncertainties The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, December 31, Finished goods $ 62,696 $ 58,701 Raw materials 86,413 127,003 Work-In-Process 61,241 55,362 Total $ 210,350 $ 241,066
Property Plant and Equipment Useful Life [Table Text Block]	Years Computers and office equipment 3 - 7 Leasehold improvements 2 Manufacturing tooling 3 - 7 Demo equipment 3 Laboratory equipment 4
Property, Plant and Equipment [Table Text Block]	September 30, December 31, Computers and office equipment $ 504,556 $ 204,903 Leasehold improvements 188,014 140,114 Manufacturing tooling 108,955 108,955 Demo equipment 73,051 85,246 Laboratory equipment 1,401,210 - Total 2,275,786 539,218 Less: Accumulated depreciation 642,036 358,765 Total Fixed Assets, Net $ 1,633,750 $ 180,453
Schedule of Finite-Lived Intangible Assets [Table Text Block]	9/30/2019 12/31/2018 Gross Carrying Accumulated Net Carrying Gross Carrying Accumulated Net Carrying Patents & Trademarks $ 336,722 $ (191,950 ) $ 144,772 $ 318,304 $ (182,559 ) $ 135,745 Licensing Fees 877,500 (92,625 ) 784,875 877,500 (48,750 ) 828,750 Developed Technology 2,882,000 (72,048 ) 2,809,952 - - - Customer Relationships 445,000 (74,166 ) 370,834 - - - Tradename 398,000 - 398,000 - - - Total $ 4,939,222 $ (430,789 ) $ 4,508,433 $ 1,195,804 $ (231,309 ) $ 964,495
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year ending December 31, Expense 2019 90,985 2020 363,941 2021 363,941 2022 265,053 2023 215,609 Thereafter 2,810,904 Total 4,110,433
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2019 2019 Domestic International Corporate/Other Total Domestic International Corporate/Other Total Revenue $ 455,878 $ 40,006 $ 26,812 $ 522,696 $ 934,621 $ 77,051 $ 52,416 $ 1,064,088 Segment Loss $ (838,742 ) $ (92,398 ) $ (3,077,372 ) $ (4,008,512 ) $ (2,697,338 ) $ (289,492 ) $ (2,849,762 ) $ (5,836,592 ) September 30, 2019 December 31, 2018 Domestic International Corporate/Other Total Domestic International Corporate/Other Total Net Assets $ (284,805 ) $ (10,387 ) $ 21,008,855 $ 20,713,663 $ 628,451 $ 41,377 $ (616,356 ) $ 53,472

Note 2 - Helomics Acquisition (

Note 2 - Helomics Acquisition (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Value of shares to Helomics shareholders (i) $ 5,612,250 Value of Helomics notes receivable forgiven (ii) 2,210,381 Value of shares to extinguish debt (iii) 6,463,309 Value of warrants issued (iv) 6,261,591 Gain on revaluation of equity method investment (v) 6,164,260 Fair value of the consideration $ 26,711,791 Less assets acquired: Cash & cash equivalents 248,102 Accounts receivable 207,769 Inventory 17,727 Prepaid expenses 15,321 Fixed assets, net 1,749,080 Intangible assets 3,725,000 Lease right of use assets 780,594 Plus liabilities assumed: Accounts payable 2,374,596 Note Payable 303,333 Accrued expenses 363,569 Lease Liability – Net of Long-term Portion 422,126 Lease liability 358,468 Total assets acquired and liabilities assumed (2,921,501 ) Goodwill $ 23,790,290
Business Acquisition, Pro Forma Information [Table Text Block]	Nine Months Ended September 30, 2019 Revenue $ 1,110,148 Net loss attributable to Predictive $ 7,249,123

Note 4 - Stockholders' Equity_2

Note 4 - Stockholders' Equity, Stock Options and Warrants (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Share-based Payment Arrangement, Activity [Table Text Block]	Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2017 276,498 $ 19.95 195,126 $ 237.40 Issued 109,886 10.13 233,615 10.67 Expired (19,456 ) 20.00 (1,071 ) 1,995.53 Exercised - - (65,006 ) 10.00 Outstanding at December 31, 2018 366,928 $ 17.03 362,664 $ 41.67 Issued 366,120 7.12 1,805,943 9.36 Expired (19,484 ) 14.73 (630 ) 3,258.32 Exercised - - (59,700 ) 0.10 Outstanding at September 30, 2019 713,564 $ 11.84 2,108,277 $ 15.33

Note 6 - Convertible Debt and_2

Note 6 - Convertible Debt and Derivative Liability (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Derivative Liability Derivative Gain Recognized to Adjustments to Derivative Liability $ 272,745 69,722 (84,627 ) (47,078 ) $ 210,762

Note 7 - Loss Per Share (Tables

Note 7 - Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30 Nine Months Ended September 30 2019 2018 2019 2018 Numerator: Net loss attributable to common shareholders per common share: basic and diluted calculation $ (4,134,313 ) $ (2,506,869 ) $ (5,982,791 ) $ (6,640,301 ) Denominator: Weighted average common shares outstanding-basic 3,146,609 1,325,261 2,581,014 1,217,829 Effect of diluted stock options, warrants and preferred stock (1) - - - - Weighted average common shares outstanding-diluted 3,146,609 1,325,261 2,581,014 1,217,829 Loss per common share-basic and diluted $ (1.31 ) $ (1.89 ) $ (2.32 ) $ (5.45 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three and Nine Months Ended 2019 2018 Options 713,564 344,889 Warrants 2,108,277 331,927 Convertible debt 103,734 504,770 Preferred stock: series B 7,925 7,925 Preferred stock: series D 350,000 - Preferred stock: series E 461,503 -

Note 8 - Leases (Tables)

Note 8 - Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Lease, Cost [Table Text Block]	September 30, 2019 Weighted average remaining lease term – operating leases in years 3.06 Weighted average discount rate – operating leases 8 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2019 $ 129,546 2020 519,751 2021 117,722 2022 42,124 2023 42,966 2024 and thereafter 153,278 Total lease payments 1,005,387 Less interest 118,675 Present value of lease liabilities $ 886,712

Note 1 - Summary of Significa_3

Note 1 - Summary of Significant Accounting Policies (Details Textual)	Oct. 28, 2019	Oct. 24, 2019USD ($)	Oct. 04, 2019USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)
Retained Earnings (Accumulated Deficit), Ending Balance				$ (68,944,537)		$ (68,944,537)			$ (63,107,945)
Cash and Cash Equivalents, at Carrying Value, Ending Balance				98,599		98,599			162,152
Operating Lease, Right-of-Use Asset				886,712		886,712
Operating Lease, Liability, Current				500,732		500,732
Depreciation, Total				130,848	$ 26,120	284,150	$ 59,442
Amortization of Intangible Assets, Total				93,421	$ 38,387	199,481	$ 46,127
Income Tax Expense (Benefit), Total						0
Unrecognized Tax Benefits, Ending Balance				0		0
Liability for Uncertainty in Income Taxes, Current				0		$ 0
Open Tax Year						2015 2016 2017 2018
Number of Operating Segments						5
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset								$ 353,007
Operating Lease, Liability, Current								$ 79,252
Convertible Promissory Note [Member]
Proceeds from Debt, Net of Issuance Costs				25,000
Private Placement [Member]
Proceeds from Issuance or Sale of Equity, Total				$ 1,562,840
Subsequent Event [Member] | The 2019 Offering [Member]
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs			$ 2,811,309
Subsequent Event [Member] | Equity Line Purchase Agreement [Member] | Investor [Member]
Issuance or Sale of Equity, Can Be Raised		$ 15,000,000
Reverse Stock Split [Member] | Subsequent Event [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10

Note 1 - Summary of Significa_4

Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Finished goods	$ 62,696	$ 58,701
Raw materials	86,413	127,003
Work-In-Process	61,241	55,362
Total	$ 210,350	$ 241,066

Note 1 - Summary of Significa_5

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	9 Months Ended
	Sep. 30, 2019
Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	2 years
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Laboratory Equipment [Member]
Property, plant, and equipment, useful life (Year)	4 years
Minimum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years
Maximum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	7 years
Maximum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years

Note 1 - Summary of Significa_6

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Property, Plant, and Equipment Gross	$ 2,275,786	$ 539,218
Less: Accumulated depreciation	642,036	358,765
Total Fixed Assets, Net	1,633,750	180,453
Office Equipment [Member]
Property, Plant, and Equipment Gross	504,556	204,903
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	188,014	140,114
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	108,955	108,955
Demo Equipment [Member]
Property, Plant, and Equipment Gross	73,051	85,246
Laboratory Equipment [Member]
Property, Plant, and Equipment Gross	$ 1,401,210

Note 1 - Summary of Significa_7

Note 1 - Summary of Significant Accounting Policies - Components of Intangible Assets (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Gross Carrying Costs	$ 4,939,222	$ 1,195,804
Accumulated Amortization	(430,789)	(231,309)
Net Carrying Amount	4,110,433	964,495
Patents and Trademarks [Member]
Gross Carrying Costs	336,722	318,304
Accumulated Amortization	(191,950)	(182,559)
Net Carrying Amount	144,772	135,745
Licensing Agreements [Member]
Gross Carrying Costs	877,500	877,500
Accumulated Amortization	(92,625)	(48,750)
Net Carrying Amount	784,875	828,750
Developed Technology Rights [Member]
Gross Carrying Costs	2,882,000
Accumulated Amortization	(72,048)
Net Carrying Amount	2,809,952
Customer Relationships [Member]
Gross Carrying Costs	445,000
Accumulated Amortization	(74,166)
Net Carrying Amount	370,834
Trade Names [Member]
Gross Carrying Costs	398,000
Accumulated Amortization
Net Carrying Amount	$ 398,000

Note 1 - Summary of Significa_8

Note 1 - Summary of Significant Accounting Policies - Estimated Future Amortization Expense (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
2019	$ 90,985
2020	363,941
2021	363,941
2022	265,053
2023	215,609
Thereafter	2,810,904
Total	$ 4,110,433	$ 964,495

Note 1 - Summary of Significa_9

Note 1 - Summary of Significant Accounting Policies - Segments (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Revenue	$ 522,696	$ 329,930	$ 1,064,088	$ 1,100,108
Segment Loss	(4,008,512)	$ (2,506,869)	(5,836,592)	$ (6,640,301)
Net Assets	20,713,663		20,713,663		$ 53,472
Domestic [Member]
Revenue	455,878		934,621
Segment Loss	(838,742)		(2,697,338)
Net Assets	(284,805)		(284,805)		628,451
International [Member]
Revenue	40,006		77,051
Segment Loss	(92,398)		(289,492)
Net Assets	(10,387)		(10,387)		41,377
Other Segments [Member]
Revenue	26,812		52,416
Segment Loss	(3,077,372)		(2,849,762)
Net Assets	$ 21,008,855		$ 21,008,855		$ (616,356)

Note 2 - Helomics Acquisition_2

Note 2 - Helomics Acquisition (Details Textual) - USD ($)	Apr. 04, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Mar. 31, 2018
Stock Issued During Period, Value, Extinguishment of Debt		$ 6,463,309
Warrants Issued		47,078
Goodwill, Ending Balance		$ 23,790,290
Notes Issued to Helomics' Noteholders [Member]
Debt Instrument, Face Amount	$ 303,333
Debt Instrument, Term	90 years
Warrants Held by Noteholders [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	583,003
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1
Helomics Holding Corp. [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage					25.00%
Business Acquisition, Percentage of Voting Interests Acquired	75.00%
Business Combination, Acquisition Related Costs	$ 656,615
Business Combination, Consideration Transferred, Total	26,711,791
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	5,612,250
Business Combination, Notes and Interest Due Forgave	$ 2,210,381
Stock Issued During Period, Shares, Extinguishment of Debt	8,637,323
Stock Issued During Period, Value, Extinguishment of Debt	$ 6,463,309
Stock Issued During Period, Shares, Acquisitions	23,741,772
Warrants Issued	$ 6,261,591
Business Acquisition, Revaluation, Gain (Loss) on Acquisition	6,164,260
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	3,725,000
Goodwill, Ending Balance	23,790,290
Helomics Holding Corp. [Member] | Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	398,000
Helomics Holding Corp. [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	$ 445,000
Finite-Lived Intangible Asset, Useful Life	3 years
Helomics Holding Corp. [Member] | Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	$ 2,882,000
Finite-Lived Intangible Asset, Useful Life	20 years
Helomics Holding Corp. [Member] | Warrants Issued to Holders of Helomics Notes and Warrants [Member]
Class of Warrant or Right Issued During Period	14,245,063
Helomics Holding Corp. [Member] | Warrants Held by Other Parties [Member]
Class of Warrant or Right Issued During Period	597,000
Helomics Holding Corp. [Member] | Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	4,000,000
Helomics Holding Corp. [Member] | Series D Convertible Preferred Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	3,500,000

Note 2 - Helomics Acquisition -

Note 2 - Helomics Acquisition - Fair value of Assets and Liabilities Assumed (Details) - USD ($)	Apr. 04, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Value of shares to extinguish debt (iii)		$ 6,463,309
Value of warrants issued (iv)		47,078
Goodwill, Ending Balance		$ 23,790,290
Helomics Holding Corp. [Member]
Value of shares to Helomics shareholders (i)	$ 5,612,250
Value of Helomics notes receivable forgiven (ii)	2,210,381
Value of shares to extinguish debt (iii)	6,463,309
Value of warrants issued (iv)	6,261,591
Business Acquisition, Revaluation, Gain (Loss) on Acquisition	6,164,260
Fair value of the consideration	26,711,791
Cash & cash equivalents	248,102
Accounts receivable	207,769
Inventory	17,727
Prepaid expenses	15,321
Fixed assets, net	1,749,080
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	3,725,000
Lease right of use assets	780,594
Accounts payable	2,374,596
Note Payable	303,333
Accrued expenses	363,569
Lease Liability – Net of Long-term Portion	422,126
Lease liability	358,468
Total assets acquired and liabilities assumed	(2,921,501)
Goodwill, Ending Balance	$ 23,790,290

Note 2 - Helomics Acquisition_3

Note 2 - Helomics Acquisition - Pro Forma Information (Details)	9 Months Ended
	Sep. 30, 2019USD ($)
Revenue	$ 1,110,148
Net loss attributable to Predictive	$ 7,249,123

Note 3 - Revenue Recognition (D

Note 3 - Revenue Recognition (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Maintenance Plan, Service Requirement, Period Subsequent to One Year Anniversary of Invoice	1 year
Accounts Receivable, after Allowance for Credit Loss, Current, Total	$ 372,119	$ 232,602
Contract with Customer, Liability, Current	$ 30,638	$ 23,065
Maintenance [Member]
Revenue, Performance Obligation, Timing	1 year
Minimum [Member]
Standard Payment Term for Customers	30 days
Maximum [Member]
Standard Payment Term for Customers	60 days

Note 4 - Stockholders' Equity_3

Note 4 - Stockholders' Equity, Stock Options and Warrants (Details Textual)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Apr. 30, 2019shares	Sep. 30, 2019USD ($)shares	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2018USD ($)	Dec. 31, 2018$ / shares
Stock Issued During Period, Value, New Issues					$ 2,755,087
Temporary Equity, Dividends, Adjustment		$ 125,801		$ 146,199
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate				0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate				82.40%
Share-based Payment Arrangement, Expense		360,146	$ 339,954	$ 2,004,366	$ 800,322
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount		$ 310,403		$ 310,403
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares				$ 7.12		$ 10.13
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition				1 year 120 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				2.03%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares				$ 6.527
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				1.39%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term				5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares				$ 3.368
Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Equity Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				3 years
Series D Preferred Stock [Member]
Preferred Stock, Shares Issued, Total | shares	3,500,000
Convertible Preferred Stock, Conversion Rate	10
Series E Convertible Preferred Stock [Member]
Convertible Preferred Stock, Conversion Rate				0.00056857
Stock Issued During Period, Value, New Issues				$ 2,577,000
Stock Issued During Period, Shares, Convertible Preferred Shares Issued | shares		173.4		257.7
Preferred Stock, Beneficial Conversion Feature		$ 182,000		$ 289,936
Temporary Equity, Dividends, Adjustment		$ 125,801		$ 146,199

Note 4 - Stockholders' Equity_4

Note 4 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Warrant [Member]
Number of Shares Outstanding (in shares)	362,664	195,126
Average Exercise Price Outstanding (in dollars per share)	$ 41.67	$ 237.40
Number of Shares Issued (in shares)	1,805,943	233,615
Average Exercise Price Issued (in dollars per share)	$ 9.36	$ 10.67
Number of Shares Expired (in shares)	(630)	(1,071)
Average Exercise Price Expired (in dollars per share)	$ 3,258.32	$ 1,995.53
Number of Shares Exercised (in shares)	(59,700)	(65,006)
Average Exercise Price Exercised (in dollars per share)	$ 0.10	$ 10
Number of Shares Outstanding (in shares)	2,108,277	362,664
Average Exercise Price Outstanding (in dollars per share)	$ 15.33	$ 41.67
Share-based Payment Arrangement, Option [Member]
Number of Shares Outstanding (in shares)	366,928	276,498
Average Exercise Price Outstanding (in dollars per share)	$ 17.03	$ 19.95
Number of Shares Issued (in shares)	366,120	109,886
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 7.12	$ 10.13
Number of Shares Expired (in shares)	(19,484)	(19,456)
Average Exercise Price Expired (in dollars per share)	$ 14.73	$ 20
Number of Shares Exercised (in shares)
Average Exercise Price Exercised (in dollars per share)
Average Exercise Price Exercised (in dollars per share)
Number of Shares Outstanding (in shares)	713,564	366,928
Average Exercise Price Outstanding (in dollars per share)	$ 11.84	$ 17.03

Note 5 - Notes Receivable (Deta

Note 5 - Notes Receivable (Details Textual) - CytoBioscience [Member] - Promissory Notes Receivable [Member]	Sep. 30, 2019USD ($)
Financing Receivable, after Allowance for Credit Loss, Total	$ 1,112,524
Notes Receivable, Interest Rate, Stated Percentage	8.00%
Note Receivable, Collateral Value	$ 1,290,000
Note Receivable Collateral Fair Value	$ 250,000

Note 6 - Convertible Debt and_3

Note 6 - Convertible Debt and Derivative Liability (Details Textual)	Sep. 27, 2019USD ($)$ / sharesshares	Sep. 28, 2018USD ($)shares	Sep. 30, 2019USD ($)shares	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)
Debt Conversion, Converted Instrument, Amount				$ 338,573
Bridge Loan			$ 4,470,380	4,470,380		$ 1,634,914
Derivative Liability, Total			210,762	210,762		$ 272,745
Embedded Derivative Financial Instruments [Member]
Derivative Liability, Total			$ 188,118	188,118
Warrant for Promissory Notes [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	68,237
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 6.21
Securities Purchase Agreements [Member] | Convertible Promissory Note [Member]
Debt Instrument, Face Amount		$ 2,297,727
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Debt Instrument, Convertible, Threshold Trading Days		20
Conversion Shares, Sum of Number of Conversion Shares Plus Inducement Shares | shares		267,833
Securities Purchase Agreements [Member] | Convertible Promissory Note [Member] | Investor 1 [Member]
Debt Instrument, Increase (Decrease), Net, Total	$ 120,000
Debt Conversion, Converted Instrument, Shares Issued | shares	15,000
Securities Purchase Agreements [Member] | Convertible Promissory Note [Member] | Investor 2 [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares			26,573
Debt Conversion, Converted Instrument, Amount			$ 100,000
Bridge Loan			$ 1,878,295	1,878,295
Securities Purchase Agreements [Member] | Promissory Note [Member]
Debt Instrument, Face Amount	$ 847,500
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument, Convertible, Threshold Trading Days	20
Proceeds from Short-term Debt, Total	$ 700,000
Debt Instrument, Convertible, Number of Equity Instruments	8,858
Debt Securities, Unrealized Gain (Loss), Total				$ (84,627)

Note 6 - Convertible Debt and_4

Note 6 - Convertible Debt and Derivative Liability - Change in Fair Value of Derivative Liabilities (Details)	9 Months Ended
	Sep. 30, 2019USD ($)
Derivative liability	$ 272,745
Derivative instrument issued	69,722
Loss recognized to revalue derivative instrument at fair value	(84,627)
Adjustments to derivative liability for warrants issued	(47,078)
Derivative liability	$ 210,762

Note 7 - Loss Per Share - Share

Note 7 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Net loss attributable to common shareholders per common share: basic and diluted calculation		$ (4,134,313)	$ (2,506,869)	$ (5,982,791)	$ (6,640,301)
Weighted average common shares outstanding-basic (in shares)		3,146,609	1,325,261	2,581,014	1,217,829
Effect of diluted stock options, warrants and preferred stock (1) (in shares)	[1]
Weighted average common shares outstanding-diluted (in shares)		3,146,609	1,325,261	2,581,014	1,217,829
Loss per common share - basic and diluted (in dollars per share)		$ (1.31)	$ (1.89)	$ (2.32)	$ (5.45)
[1]	The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive: Three and Nine Months Ended September 30 2019 2018 Options 713,564 344,889 Warrants 2,108,277 331,927 Convertible debt 103,734 504,770 Preferred stock: series B 7,925 7,925 Preferred stock: series D 350,000 - Preferred stock: series E 461,503 -

Note 7 - Loss Per Share - Antid

Note 7 - Loss Per Share - Antidilutive Securities Excluded from the Diluted Calculations (Details) - shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares)	713,564	344,889
Warrant [Member]
Antidilutive Securities (in shares)	2,108,277	331,927
Convertible Debt Securities [Member]
Antidilutive Securities (in shares)	103,734	504,770
Series B Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)	7,925	7,925
Series D Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)	350,000
Series E Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)	461,503

Note 8 - Leases (Details Textua

Note 8 - Leases (Details Textual)	3 Months Ended		9 Months Ended
	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Jun. 15, 2018ft²	Feb. 01, 2018ft²	Oct. 17, 2017ft²
Operating Lease, Expense | $	$ 184,046	$ 27,807	$ 367,180	$ 64,986
Corporate Office, Minnesota [Member]
Lessee, Operating Lease, Term of Contract						3 years
Area of Real Estate Property						5,773
Corporate Office, Minnesota [Member] | Office Space [Member]
Area of Real Estate Property						2,945
Corporate Office, Minnesota [Member] | Manufacturing Facility [Member]
Area of Real Estate Property						2,828
Skyline Medical Europe’s Offices Lease [Member]
Area of Real Estate Property					2,000
Skyline Medical Europe’s Offices Lease [Member] | Office Space [Member]
Area of Real Estate Property					1,250
Skyline Medical Europe’s Offices Lease [Member] | Storage Space [Member]
Area of Real Estate Property					750
Helomics' Offices [Member]
Lessee, Operating Lease, Term of Contract							3 years
Area of Real Estate Property							17,417
Helomics' Offices [Member] | Office Space [Member]
Area of Real Estate Property							1,000
Helomics' Offices [Member] | Laboratory [Member]
Area of Real Estate Property							16,417

Note 8 - Leases - Lease Informa

Note 8 - Leases - Lease Information (Details)	Sep. 30, 2019
Weighted average remaining lease term – operating leases in years (Year)	3 years 21 days
Weighted average discount rate – operating leases	8.00%

Note 8 - Leases - Rent Obligati

Note 8 - Leases - Rent Obligation (Details)	Sep. 30, 2019USD ($)
2019	$ 129,546
2020	519,751
2021	117,722
2022	42,124
2023	42,966
2024 and thereafter	153,278
Total lease payments	1,005,387
Less interest	118,675
Present value of lease liabilities	$ 886,712

Note 9 - Related Party Transa_2

Note 9 - Related Party Transactions (Details Textual) - USD ($)	May 21, 2019	May 01, 2019	Sep. 30, 2019	Sep. 30, 2019	May 30, 2019	Dec. 31, 2018
Derivative Liability, Total			$ 210,762	$ 210,762		$ 272,745
Embedded Derivative Financial Instruments [Member]
Derivative Liability, Total			$ 188,118	188,118
Director [Member]
Related Party Transaction, Monthly Cash Payment		$ 13,500
Chief Executive Officer [Member]
Proceeds from Related Party Debt	$ 1,620,000
Chief Executive Officer [Member] | Loans From Dr. Schwartz [Member]
Proceeds from Related Party Debt				300,000
Debt Instrument, Interest Rate, Stated Percentage					8.00%
Chief Executive Officer [Member] | Schwartz Warrant [Member]
Class of Warrant or Right Issued During Period			3,451
Chief Executive Officer [Member] | Schwartz Warrant [Member] | Embedded Derivative Financial Instruments [Member]
Derivative Liability, Change in Fair Value Due to Issuance of Warrants			$ 14,863
Derivative Liability, Total			$ 22,644	$ 22,644

Note 10 - Subsequent Events (De

Note 10 - Subsequent Events (Details Textual)	Oct. 28, 2019	Oct. 24, 2019USD ($)shares	Oct. 04, 2019USD ($)$ / sharesshares	Oct. 01, 2019shares	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)$ / shares
Shares Issued, Price Per Share | $ / shares						$ 11.80
Proceeds from Issuance of Common Stock					$ 2,479,708	$ 2,959,509
Subsequent Event [Member] | Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10
Subsequent Event [Member] | Right to Purchase Units [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			63,355
Right to Purchase Units, Percentage			10.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 6.25
Subsequent Event [Member] | The 2019 Offering [Member]
Stock Issued During Period, Shares, New Issues | shares				633,554
Shares Issued, Price Per Share | $ / shares			$ 5
Proceeds from Issuance of Common Stock			$ 3,167,769
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs			$ 2,811,309
Subsequent Event [Member] | Equity Line Purchase Agreement [Member] | Investor [Member]
Issuance or Sale of Equity, Can Be Raised		$ 15,000,000
Subsequent Event [Member] | Commitment Share [Member] | Investor [Member]
Stock Issued During Period, Shares, New Issues | shares		104,651